PMID- 7621588
OWN - NLM
STAT- MEDLINE
DCOM- 19950830
LR  - 20190512
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 101
IP  - 1
DP  - 1995 Jul
TI  - Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic 
      vasculitis with high-dose intravenous immunoglobulin.
PG  - 2-7
AB  - In this uncontrolled study 15 patients with ANCA-associated systemic vasculitis, 
      who were poor responders to conventional therapy, were treated with single or 
      multiple courses of intravenous immunoglobulin (IVIG), 30 g/day over 5 days. 
      Clinical and serological evaluation was performed before and 4 weeks after IVIG. 
      Six of the 15 patients experienced clinically significant benefit from IVIG. 
      Improvement was confined to single organ manifestations (skin, ENT findings), no 
      improvement was seen with conjunctivitis and scleritis, pericarditis or 
      nephritis. No patient experienced complete remission after IVIG. Repeated courses 
      of IVIG at 4-week intervals were no more effective than single courses. In six 
      anti-proteinase 3 (PR3)-positive patients pretreatment sera were incubated with 
      F(ab')2 fragments of the IVIG preparation in vitro to measure the inhibitory 
      effect of IVIG on anti-PR3 activity. An inhibition of anti-PR3 activity by 25-70% 
      was observed; this did not correlate with clinical effects. Approximately 40% of 
      patients benefited from IVIG treatment, though complete remission of disease 
      activity did not occur. Neither clinical characteristics nor the inhibitory 
      effect of the IVIG preparation on serum anti-PR3 activity in vitro predicted 
      clinical response to this treatment modality.
FAU - Richter, C
AU  - Richter C
AD  - Department of Rheumatology, University of Lubeck, Germany.
FAU - Schnabel, A
AU  - Schnabel A
FAU - Csernok, E
AU  - Csernok E
FAU - De Groot, K
AU  - De Groot K
FAU - Reinhold-Keller, E
AU  - Reinhold-Keller E
FAU - Gross, W L
AU  - Gross WL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Receptors, Interleukin-2)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.76 (Myeloblastin)
SB  - IM
MH  - Adult
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - Autoantibodies/*analysis
MH  - C-Reactive Protein/analysis
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myeloblastin
MH  - Receptors, Interleukin-2/immunology
MH  - Serine Endopeptidases/immunology
MH  - Vasculitis/*immunology/*therapy
PMC - PMC1553313
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
PMCR- 1996/07/01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
PHST- 1996/07/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.1995.tb02268.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 1995 Jul;101(1):2-7. doi: 10.1111/j.1365-2249.1995.tb02268.x.